Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 7Phase 1 2Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 218Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 91Fluorouracil 87Bevacizumab 83Nivolumab 74Leucovorin 72Rituximab 70Vincristine 67durvalumab 66Lenalidomide 63Etoposide 62atezolizumab 61Radiation 61Irinotecan 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × patritumab deruxtecan × 1 year × Clear all
NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡